Today's Rundown Featured Story | | | Friday, February 8, 2019 Sangamo Therapeutics has posted lackluster data from a phase 1/2 trial of genome-editing therapy SB-913. The treatment failed to have the hoped-for effects on patients with the rare disease MPS II, causing investors to drive Sangamo’s stock down 30%. |
|
|
Top Stories Friday, February 8, 2019 Axovant Sciences has renamed itself Axovant Gene Therapies to put a seal on its switch from repurposing small-molecule drugs toward becoming a player at the cutting edge of genetic medicine. Friday, February 8, 2019 Seres Therapeutics has cut about 30% of its workforce and said goodbye to its chief scientific officer as it narrows its clinical efforts. It will instead focus on what it described as its “highest priority” late-stage microbiome programs for ulcerative colitis and C. difficile infections, as well as a planned immuno-oncology study. Friday, February 8, 2019 UniQure has posted 12-week data on its hemophilia B gene therapy. The update suggests FIX activity increases seen at six weeks are sustainable, giving uniQure a boost as it races Spark Therapeutics to market. Friday, February 8, 2019 Late last month, Gossamer Bio filed to raise up to $230 million in a fixed-price IPO so it could go public despite the partial shutdown of the U.S. government. Now that the government has reopened, the San Diego biotech has returned to its original plan, pricing its traditional IPO at $276 million. Thursday, February 7, 2019 After a century of research, there's still no proven way to give protein drugs such as insulin by mouth, which is considered the holy grail of drug delivery. Now, an MIT-Novo Nordisk team has come up with a pill, inspired by the tortoise, that they say could one day replace injections for diabetes patients. Thursday, February 7, 2019 In this week's EuroBiotech Report, Sanofi dumps drugs and posts data on Darzalex rival, GenSight phase 3 misses the mark and Galapagos bags an Evotec asset. Friday, February 8, 2019 Lacking overall survival data, Takeda pulls an FDA Ninlaro filing in maintenance setting; the Japanese pharma is also ordered to pay $155 million in a Shire-Bayer hemophilia patent case; some Chinese investors back a New York cancer startup's $60.75 million financing round; and more. Friday, February 8, 2019 Chimerix’s CEO departs and is replaced by a trio of officers; Decibel hires new CMO ahead of proof-of-concept hearing loss studies; and Kiadis poaches Ablynx CSO as it awaits HSCT booster approval in the EU. Those moves plus more hirings, firings and retirings throughout the industry. | This week's sponsor is Camargo. | |  | [Webinar] Maximizing the Value of Your Drug Development Program
Thursday, February 21 | 11am ET / 8am PT
This webinar will benefit executives at Biotech and Pharmaceutical companies interested in learning more about 505(b)(2) drug development and how to save time and money while maximizing the value of their drug development program. Register Now! |
Enrollment Showcase | | | Sponsored by: Drexel University Online Drexel University’s online graduate programs in biomedicine, clinical research, drug discovery, and molecular medicine were developed with working professionals in mind, providing you with the education, practical skills, and competitive edge you need to be successful in your career. Learn more. |
|
|
Resources Sponsored by: Patheon, part of Thermo Fisher Scientific When a biologics company prepares to launch a new product, it must forecast the manufacturing capacity it will need, factoring in its estimate of the size of future sales, the timing of the launch, the dosage of the product, its strategy for building its market and a host of other variables. Sponsored by: Oracle Health Sciences 92% of survey respondents make changes to their RTSM/IRT systems due to study changes. See what else puts a strain on their clinical trials. Download the Research Whitepaper. Sponsored by: Patheon, part of Thermo Fisher Scientific Download this whitepaper to learn more. Sponsored by: The Kinetix Group Explore how the pharma industry can adapt its approach to the changing healthcare marketplace in the era of the Quadruple Aim Sponsored by: Cofactor Genomics Learn how Health Expression Models provide increased sensitivity, specificity, and accuracy for characterizing immune response in solid tumor specimens. Sponsored by: BioAnalytix, Inc. This whitepaper reviews fundamental aspects of HCPs that pertain to biologic drug development and presents current and emerging approaches to HCP analysis. Sponsored by: Veradigm Clinical trials take too long and cost too much—here's what needs to change. Sponsored by: AlphaSense It’s never been more challenging to stay on top of competitive factors impacting your industry. Discover how AI can help competitive teams achieve more proactive market intelligence. Sponsored by: Reprints Desk, Inc. Go from Search to Full-Text Scientific Papers in a Single Click! Sponsored by: Blue Latitude Health This white paper consists of original data and expert interviews. Download it today for exclusive tools, tips and analysis on achieving launch excellence in challenging pharma markets. Sponsored by: Outer Edge Technology With FDA approval imminent, start-up Life Sciences company partners with an industry focused MSP to design and manage its regulated cloud-based infrastructure to speed time to market. Sponsored by: DeciBio Consulting With the liquid biopsy market maturing and >80 companies still competing with liquid biopsy offerings, it is crucial for investors to be able to cut through the noise and identify the winners. Presented by: Veeva Share your thoughts on the life sciences industry's progress in improving study execution. Sponsored by: Biotech Primer The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry. | 
